Stock Scorecard
Stock Summary for Scinai Immunotherapeutics Ltd (SCNI) - $0.45 as of 6/4/2026 8:03:24 AM EST
Total Score
11 out of 30
Safety Score
22 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for SCNI
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for SCNI
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for SCNI
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for SCNI
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for SCNI (22 out of 100)
| Stock Price Rating (Max of 10) | 1 |
| Historical Stock Price Rating (Max of 10) | 7 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 8 |
| Analyst Buy Ratings (Max of 5) | 0 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for SCNI
Financial Details for SCNI
Company Overview |
|
|---|---|
| Ticker | SCNI |
| Company Name | Scinai Immunotherapeutics Ltd |
| Country | USA |
| Description | Scinai Immunotherapeutics Ltd is a cutting-edge biotechnology company specializing in the development of innovative immunotherapy solutions aimed at treating cancer and autoimmune disorders. Utilizing its proprietary immune modulation platform, Scinai is advancing a robust clinical pipeline that focuses on delivering transformative therapies to improve patient outcomes. With a highly experienced leadership team and a commitment to rigorous research, the company is well-positioned to capitalize on the growing demand for advanced immunotherapeutics in the global healthcare landscape. Strategic partnerships further enhance Scinai's potential for significant growth, establishing it as a key player in the biopharmaceutical sector. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 3/31/2026 |
| Next Earnings Date | 7/1/2026 |
Stock Price History |
|
| Last Day Price | 0.45 |
| Price 4 Years Ago | 29.60 |
| Last Day Price Updated | 6/4/2026 8:03:24 AM EST |
| Last Day Volume | 186,307 |
| Average Daily Volume | 6,998,493 |
| 52-Week High | 3.12 |
| 52-Week Low | 0.41 |
| Last Price to 52 Week Low | 9.76% |
Valuation Measures |
|
| Trailing PE | 0.00 |
| Industry PE | 101.33 |
| Sector PE | 65.46 |
| 5-Year Average PE | -221.90 |
| Free Cash Flow Ratio | 1.07 |
| Industry Free Cash Flow Ratio | 31.52 |
| Sector Free Cash Flow Ratio | 33.13 |
| Current Ratio Most Recent Quarter | 1.30 |
| Total Cash Per Share | 0.42 |
| Book Value Per Share Most Recent Quarter | 0.71 |
| Price to Book Ratio | 0.77 |
| Industry Price to Book Ratio | 5.56 |
| Sector Price to Book Ratio | 7.38 |
| Price to Sales Ratio Twelve Trailing Months | 1.39 |
| Industry Price to Sales Ratio Twelve Trailing Months | 8.90 |
| Sector Price to Sales Ratio Twelve Trailing Months | 4.69 |
| Analyst Buy Ratings | N/A |
| Analyst Strong Buy Ratings | N/A |
Share Statistics |
|
| Total Shares Outstanding | 3,959,800 |
| Market Capitalization | 1,781,910 |
| Institutional Ownership | 3.19% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 87.20% |
| Annual Earnings Growth | -273.21% |
| Reported EPS 12 Trailing Months | 0.00 |
| Reported EPS Past Year | -1.37 |
| Reported EPS Prior Year | 4.98 |
| Net Income Twelve Trailing Months | -8,307,000 |
| Net Income Past Year | -8,307,000 |
| Net Income Prior Year | 4,796,000 |
| Quarterly Revenue Growth YOY | 30.60% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | -702.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 1,661,000 |
| Total Cash Past Year | 1,661,000 |
| Total Cash Prior Year | 1,964,000 |
| Net Cash Position Most Recent Quarter | 1,368,000 |
| Net Cash Position Past Year | 1,367,000 |
| Long Term Debt Past Year | 294,000 |
| Long Term Debt Prior Year | 260,000 |
| Total Debt Most Recent Quarter | 293,000 |
| Equity to Debt Ratio Past Year | 0.96 |
| Equity to Debt Ratio Most Recent Quarter | 0.97 |
| Total Stockholder Equity Past Year | 8,103,000 |
| Total Stockholder Equity Prior Year | 9,977,000 |
| Total Stockholder Equity Most Recent Quarter | 8,103,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -5,705,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.44 |
| Free Cash Flow Past Year | -6,055,000 |
| Free Cash Flow Prior Year | -6,347,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | False |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 2.19 |
| RSI | 0.00 |
| 50-Day SMA | 3.80 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 15.22 |
System |
|
| Modified | 6/4/2026 8:03:25 AM EST |